Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 7/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13980130 | 1.00 | CYP2C9 (0.39) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL13980127 | 0.92 | SPHK1 (0.39) | CYP2C9MAPTALOX5SPHK1SPHK2 | |
| SCHEMBL13980209 | 0.91 | ALOX5 (0.34) | ALOX5SPHK1SPHK2 | |
| SCHEMBL12511077 | 0.87 | CYP2C9 (0.39) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL12433788 | 0.86 | SPHK1 (0.41) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL13026363 | 0.84 | SLC6A2 (0.31) | — | |
| SCHEMBL13980224 | 0.83 | CYP2C9 (0.34) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL13980114 | 0.83 | SPHK1 (0.38) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL12984463 | 0.83 | OPRL1 (0.35) | CYP2C9ALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL14035140 | 0.83 | ALOX5 (0.33) | ALOX5SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981486-B2 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | JNC CORPORATION (JP) | 2011-07-19 | — | — | US | disclosed |
| US-7846513-B2 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORPORATION (JP) | 2010-12-07 | — | — | US | disclosed |
| EP-1997867-B1 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-20090230356-A1 | COMPOUND HAVING ALKYL ON BENZENE RING, LIQUID CRYSTAL COMPOSITION HAVING THE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE HAVING THE LIQUID CRYSTAL COMPOSITION | CHISSO CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1997867-A1 | Compound having alkyl on benzene ring, liquid crystal composition having the compound, and liquid crystal display device having the liquid crystal composition | CHISSO CORPORATION (JP) | 2008-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090230356-A1 | COMPOUND HAVING ALKYL ON BENZENE RING, LIQUID CRYSTAL COMPOSITION HAVING THE COMPOUND, AND LIQUID CRYSTAL DISPLAY DEVICE HAVING THE LIQUID CRYSTAL COMPOSITION | BRD1, CNOT1, CXCR1 | CYP2C9 160/4885ALDH1A1 1134/4885LMNA 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.